Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

38.45 -2.02 (-4.99%)

Streaming Delayed Price Updated: 10:55 AM EDT, Mar 26, 2026 Add to My Watchlist

Price and Volume

Volume	781,544
Open	38.76
Bid (Size)	38.43 (300)
Ask (Size)	38.49 (300)
Prev. Close	40.47
Today's Range	37.88 - 40.12
52wk Range	28.66 - 117.33
Shares Outstanding	115,926,629
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MarketMinute: Corcept Therapeutics (CORT) Surges 19.66% on Surprise FDA Approval and Oncology Breakthrough

Today 10:30 EDT

The biotechnology sector witnessed a seismic shift on March 26, 2026, as shares of Corcept Therapeutics (NASDAQ: CORT) surged 19.66% in heavy trading. The rally, which added nearly $1 billion to the...

Via MarketMinute

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

Today 9:37 EDT

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Performance

YTD	+0.7%	+0.7%
1 Month	+8.8%	+8.8%
3 Month	-54.0%	-54.0%
6 Month	-54.1%	-54.1%
1 Year	-34.1%	-34.1%

More News

Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT

March 25, 2026

From SkyMedia, LLC

Via GlobeNewswire

Corcept Therapeutics Inc (NASDAQ:CORT): A GARP Pick with Accelerating Growth and a Solid Financial Base ↗

March 18, 2026

Via Chartmill

Why Investors Strapped a Rocket to Corcept Therapeutics Stock on Wednesday ↗

March 25, 2026

Via The Motley Fool

Wednesday's session: top gainers and losers ↗

March 25, 2026

Via Chartmill

FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer

March 25, 2026

From Corcept Therapeutics Incorporated

Via Business Wire

What's Behind The Jump In Corcept Therapeutics Stock? ↗

March 25, 2026

Via Benzinga

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

March 25, 2026

Via NewMediaWire

Deadline Approaching for Investors of Corcept Therapeutics, Inc. (CORT) - Contact Kaplan Fox Before April 21, 2026

March 25, 2026

Via TheNewswire.com

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

March 24, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline on April 21, 2026

March 24, 2026

Via NewMediaWire

Kaplan Fox Continues to Alert Investors of a Securities Class Action Against Corcept Therapeutics, Inc. (NASDAQ: CORT) - Deadline on April 21, 2026

March 24, 2026

Via TheNewswire.com

CORT DEADLINE NOTICE: Corcept Therapeutics Incorporated Investors Encouraged to Contact Kirby McInerney LLP By April 21, 2026

March 24, 2026

From Kirby McInerney LLP

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

March 24, 2026

From Pomerantz LLP

Via GlobeNewswire

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT

March 23, 2026

From The Rosen Law Firm PA

Via GlobeNewswire

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

March 23, 2026

From Schall Law

Via GlobeNewswire

Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks

March 22, 2026

Via StockStory

CORT INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of Corcept Therapeutics Incorporated Investors

March 19, 2026

From Kirby McInerney LLP

Via GlobeNewswire

March 18, 2026

From SkyMedia, LLC

Via GlobeNewswire

Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

March 17, 2026

From Kahn Swick & Foti, LLC

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming Deadlines – CORT

March 17, 2026

From Pomerantz LLP

Via GlobeNewswire

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

March 17, 2026

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)

March 17, 2026

From Bernstein Liebhard LLP

Via GlobeNewswire

CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm

March 13, 2026

From Schall Law

Via GlobeNewswire

Frequently Asked Questions

Is Corcept Therapeutics Incorporated - Common Stock publicly traded?

Yes, Corcept Therapeutics Incorporated - Common Stock is publicly traded.

What exchange does Corcept Therapeutics Incorporated - Common Stock trade on?

Corcept Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Corcept Therapeutics Incorporated - Common Stock?

The ticker symbol for Corcept Therapeutics Incorporated - Common Stock is CORT on the Nasdaq Stock Market

What is the current price of Corcept Therapeutics Incorporated - Common Stock?

The current price of Corcept Therapeutics Incorporated - Common Stock is 38.45

When was Corcept Therapeutics Incorporated - Common Stock last traded?

The last trade of Corcept Therapeutics Incorporated - Common Stock was at 03/26/26 10:55 AM ET

What is the market capitalization of Corcept Therapeutics Incorporated - Common Stock?

The market capitalization of Corcept Therapeutics Incorporated - Common Stock is 4.46B

How many shares of Corcept Therapeutics Incorporated - Common Stock are outstanding?

Corcept Therapeutics Incorporated - Common Stock has 4B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.